Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Absci (Nasdaq: ABSI) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Management is scheduled to present on Wednesday, January 14, 2026 at 3:45 p.m. PT (6:45 p.m. ET). Interested parties can watch a live and archived webcast via the company's investor relations site at investors.absci.com.
The presentation will cover the company's clinical-stage programs and AI-driven therapeutic platform; a webcast will be available for on-demand viewing after the presentation.
Positive
- None.
Negative
- None.
News Market Reaction – ABSI
On the day this news was published, ABSI gained 4.72%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Several biotech peers showed weakness, with CGEM -9.08%, INBX -5.95%, and LXRX -6.11%, while YMAB was slightly positive at +0.23%. With no peers in the momentum scanner and mixed moves, ABSI’s action appears more stock-specific than a broad sector trade.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 11 | Scientific data update | Positive | -3.3% | New human ex vivo ABS-201 data suggesting potential to reverse follicle miniaturization. |
| Dec 10 | Awareness partnership | Positive | +12.8% | Partnership with Landon Donovan to highlight hair loss patient voice and ABS-201 program. |
| Dec 04 | Clinical trial start | Positive | +11.7% | First participants dosed in Phase 1/2a HEADLINE trial of ABS-201 for AGA. |
| Nov 12 | Earnings and updates | Negative | -1.4% | Q3 2025 results with lower revenue and sizeable net loss alongside pipeline updates. |
| Oct 29 | Earnings scheduling | Neutral | -0.7% | Announcement of timing for Q3 2025 results call and webcast logistics. |
Recent news shows mixed price reactions: positive clinical and partnership updates often aligned with gains, while other scientific or financial updates sometimes saw negative follow‑through.
Over the past few months, Absci has advanced its pipeline and visibility. On Dec 4, first participants were dosed in the Phase 1/2a HEADLINE™ trial of ABS-201, with a +11.7% reaction. A partnership with Landon Donovan on Dec 10 drew a +12.78% move. New ex vivo ABS-201 data on Dec 11 coincided with a -3.27% reaction, showing not all scientific updates are rewarded. Third‑quarter 2025 results on Nov 12 brought revenue softness and a -1.45% move. Today’s conference participation fits the pattern of ongoing investor outreach and communication.
Regulatory & Risk Context
An effective Form S-3 shelf dated Aug 12, 2025 allows Absci to offer up to $400,000,000 of securities, including a prospectus for up to $100,000,000 of common stock via TD Securities (USA) LLC. The shelf is preliminary and proceeds are earmarked for general corporate purposes with broad management discretion.
Market Pulse Summary
This announcement centers on Absci’s participation in the 44th Annual J.P. Morgan Healthcare Conference, with a scheduled presentation on January 14. It extends a steady pattern of investor outreach, complementing recent clinical and corporate updates on ABS-201 and broader pipeline progress. Investors following the story may focus on what new details, if any, emerge from the conference regarding development timelines, partnering strategy, and use of capital under the existing $400,000,000 shelf registration.
Key Terms
generative AI technical
AI-generated analysis. Not financial advice.
VANCOUVER, Wash. and NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced the company will be participating in the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
Absci management is scheduled to present on Wednesday, January 14th at 3:45 p.m. Pacific Time (6:45 p.m. Eastern Time). Interested parties may access a live and archived webcast of the presentation on the company’s investor relations website at: investors.absci.com.
About Absci
Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics including ABS-201™, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern hair-loss. ABS-201 is also being investigated as a potential “best-in-class” therapeutic for endometriosis, a condition with significant unmet medical need and market potential. Absci is headquartered in Vancouver, WA, with an AI Research Lab in New York City, and Innovation Center in Switzerland. Learn more at www.absci.com or follow us on LinkedIn (@absci), X (@Abscibio) and YouTube.
Absci® standard character mark, ABS-201™, and Integrated Drug Creation™ are trademarks and registered trademarks of Absci Corporation.
Investor Contact
Alex Khan
VP, Finance & Investor Relations
investors@absci.com
Media Contact
press@absci.com
FAQ
When will Absci (ABSI) present at the 44th J.P. Morgan Healthcare Conference?
How can investors watch Absci's (ABSI) J.P. Morgan presentation?
What topics will Absci (ABSI) cover during the J.P. Morgan presentation?
Will the Absci (ABSI) webcast be available after the conference?
Where is the 44th Annual J.P. Morgan Healthcare Conference being held?
